market product solut
diagnost life scienc research market
requir disclosur end report
guid miss us margin target revenu
view current cl king meet event calendar coverag univers
bio-rad post decent hit revenu number exactli beat us
ep line even strip tax benefit foreign exchang fx
headwind subsid fx tailwind contribut
model bio-rad oper margin miss us addit
revenu growth could help compani easili achiev oper
margin target thesi bio-rad margin expans stori
well-understood go-forward basi compani need gener high
end growth target rang stock work view
dont enough visibl happen reiter neutral rate
number bio-rad post revenu report
foreign currenc neutral fxn vs street
compar quarter bio-rad revenu
compani post ep vs street
estim bio-rad post ep adjust item
cite confer call arriv non-gaap ep figur
beat estim
annual number guidanc bio-rad post annual revenu
vs full-year ep vs
guidanc bio-rad initi fxn revenu growth guidanc
littl ahead estim impli report
growth close dollar declin significantli oper
margin came bit target addit tax rate
came estim bio-rad announc would
begin provid non-gaap account welcom chang mani
life scienc life scienc revenu
fxn vs came exactli estim
note signific strength sale droplet digit pcr cell biolog
process media bio-rad expect fxn growth
diagnost compani gener clinic diagnost sale
fxn vs come right
estim bio-rad cite blood type immunolog qualiti control
strong contributor compani expect fxn growth
bucket
singl cell bio-rad singl cell opportun increment meaning
rapidli grow ddpcr busi concern
partnership ilmna add increment think
street bake meaning contribut
model modestli increas revenu estim
lower ep number
model ep vs prior estim
revenu vs previou estim chang
ep model reflect slightli slower margin ramp tax rate
littl higher initi thought bio-rad
abil cut cost
chang health care industry/regul
failur protect ip patent
lawsuit genom
lab consolid europ
page
